OCUL Ocular Therapeutix Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 12 March 2020 Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

   Fourth Quarter DEXTENZA® Net Product Revenue of $1.6 million, a 433% Sequential Increase; Guiding First Quarter Total Net Product Revenue of $3.0 million to $3.2 million Presented Interim Clinical Data Releases for

2. 05 March 2020 Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

3. 03 March 2020 Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced

4. 25 February 2020 Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

5. 07 February 2020 Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will today present data

6. 26 November 2019 Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

7. 19 November 2019 Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

   Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

8. 14 November 2019 Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

9. 12 November 2019 Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

   Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quarter of 2020 Topline

10. 08 November 2019 Ocular Therapeutix Announces Strategic Update and Operational Restructuring

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational

11. 05 November 2019 Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

12. 05 November 2019 Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

13. 01 October 2019 Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

14. 26 September 2019 Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

15. 29 August 2019 Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that